Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cilloni

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
Leukemia Research|March 10, 2009
Is WT1 helping the molecular monitoring of minimal residual disease to get easier in acute myeloid leukaemia?Daniela Cilloni
Seminars in Hematology|June 5, 2003
Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapyDaniela Cilloni, Giuseppe Saglio
Acta Haematologica|June 5, 2004
WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndromeDaniela Cilloni, Giuseppe Saglio
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2011
Molecular pathways: BCR-ABLDaniela Cilloni, Giuseppe Saglio
Haematologica|February 3, 2004
Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatmentGiuseppe Saglio, Daniela Cilloni
Best Practice & Research. Clinical Haematology|December 5, 2009
CML: a model for targeted therapyDaniela Cilloni, Giuseppe Saglio
Blood and Lymphatic Cancer : Targets and Therapy|December 7, 2019
Strategies for minimal residual disease detection: current perspectivesGiacomo Andreani, Daniela Cilloni
Cancers|September 14, 2024
The Ubiquitin-Conjugating Enzyme E2 O (UBE2O) and Its Therapeutic Potential in Human Leukemias and Solid TumorsBeatrice Maffeo, Daniela Cilloni
Advances in Hematology|July 31, 2010
Iron chelation therapy in myelodysplastic syndromesEmanuela Messa, Daniela Cilloni, Giuseppe Saglio
Immunology Letters|October 2, 2013
New possibilities to exploit the potentiality of cord blood cells in the context of transplantationFrancesco Frassoni, Daniela Cilloni, Marina Podestà
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
Leukemia Research|March 10, 2009
Is WT1 helping the molecular monitoring of minimal residual disease to get easier in acute myeloid leukaemia?Daniela Cilloni
Seminars in Hematology|June 5, 2003
Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapyDaniela Cilloni, Giuseppe Saglio
Acta Haematologica|June 5, 2004
WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndromeDaniela Cilloni, Giuseppe Saglio
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2011
Molecular pathways: BCR-ABLDaniela Cilloni, Giuseppe Saglio
Haematologica|February 3, 2004
Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatmentGiuseppe Saglio, Daniela Cilloni
Best Practice & Research. Clinical Haematology|December 5, 2009
CML: a model for targeted therapyDaniela Cilloni, Giuseppe Saglio
Blood and Lymphatic Cancer : Targets and Therapy|December 7, 2019
Strategies for minimal residual disease detection: current perspectivesGiacomo Andreani, Daniela Cilloni
Cancers|September 14, 2024
The Ubiquitin-Conjugating Enzyme E2 O (UBE2O) and Its Therapeutic Potential in Human Leukemias and Solid TumorsBeatrice Maffeo, Daniela Cilloni
Advances in Hematology|July 31, 2010
Iron chelation therapy in myelodysplastic syndromesEmanuela Messa, Daniela Cilloni, Giuseppe Saglio
Immunology Letters|October 2, 2013
New possibilities to exploit the potentiality of cord blood cells in the context of transplantationFrancesco Frassoni, Daniela Cilloni, Marina Podestà
Pageof 20